Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioArctic AB Class B ( ($SE:BIOA.B) ) has provided an announcement.
BioArctic AB announced it will release its second quarter report for 2025 on August 28, followed by an audiocast and teleconference for investors, analysts, and media. This event will provide insights into the company’s financial performance and strategic direction, potentially impacting investor perceptions and market positioning.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK243.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a Swedish research-based biopharmaceutical company specializing in innovative treatments for neurodegenerative diseases. The company is known for developing Leqembi® (lecanemab), the first drug proven to slow the progression of Alzheimer’s disease. BioArctic collaborates with Eisai for global regulatory interactions and commercialization. The company also has a diverse research portfolio targeting Parkinson’s disease, ALS, and Alzheimer’s disease, utilizing its proprietary BrainTransporter™ technology to enhance treatment efficacy.
Average Trading Volume: 214,103
Technical Sentiment Signal: Strong Buy
Current Market Cap: SEK20.86B
See more insights into BIOA.B stock on TipRanks’ Stock Analysis page.